Puhe Pharmaceutical Overview
- Year Founded
-
2020
- Status
-
Private
- Latest Deal Type
-
Series A
- Investors
-
6
Puhe Pharmaceutical General Information
Description
Operator of a pharmaceutical company intended to develop innovative small-molecule drugs. The company offers a pipeline of clinical-stage drugs focused on targeted therapies, enabling patients to get proper treatment of their diseases.
Contact Information
Website
www.puhebiopharma.comCorporate Office
- Number 108, Yuxin Road
- Suzhou Industrial Park
- Suzhou, Jiangsu 215000
- China
Corporate Office
- Number 108, Yuxin Road
- Suzhou Industrial Park
- Suzhou, Jiangsu 215000
- China
Puhe Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 25-Sep-2025 | Completed | Generating Revenue | |||
| 1. Secondary Transaction - Private | 23-Dec-2021 | Completed | Startup |
Puhe Pharmaceutical Patents
Puhe Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026214690-A1 | Mat2a inhibitor | Pending | 10-Apr-2025 | ||
| WO-2026208920-A1 | Pyrimidinylaminobenzenes for treating cancer with an egfr pacc mutation | Pending | 02-Apr-2025 | ||
| WO-2026153427-A1 | Polycyclic compound functioning as mat2a inhibitor | Pending | 17-Jan-2025 | ||
| WO-2026130474-A1 | Macrocyclic compound as pan-ras mutant inhibitor | Pending | 20-Dec-2024 | ||
| WO-2025201480-A1 | Spiro compound as kras mutant inhibitor | Pending | 28-Mar-2024 |
Puhe Pharmaceutical Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CAS Star | Venture Capital | Minority | ||
| Hankang Capital | Growth/Expansion | Minority | ||
| Suzhou Equity Investment Fund Management | Fund of Funds | Minority | ||
| Trinity Innovation Fund | Venture Capital | Minority | ||
| YuanBio Venture Capital | Venture Capital | Minority |
Puhe Pharmaceutical FAQs
-
When was Puhe Pharmaceutical founded?
Puhe Pharmaceutical was founded in 2020.
-
Where is Puhe Pharmaceutical headquartered?
Puhe Pharmaceutical is headquartered in Suzhou, China.
-
What industry is Puhe Pharmaceutical in?
Puhe Pharmaceutical’s primary industry is Drug Discovery.
-
Is Puhe Pharmaceutical a private or public company?
Puhe Pharmaceutical is a Private company.
-
What is Puhe Pharmaceutical’s current revenue?
The current revenue for Puhe Pharmaceutical is .
-
Who are Puhe Pharmaceutical’s investors?
CAS Star, Hankang Capital, Suzhou Equity Investment Fund Management, Trinity Innovation Fund, and YuanBio Venture Capital are 5 of 6 investors who have invested in Puhe Pharmaceutical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process